Free tool
FAERS Monitor: Lithobid
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 018027 or its brand name (Lithobid, Lithium Carbonate). Reports on generic versions are filed under their own applications.
Reports
16,978
Serious
13,565
80% of reports
Hospitalization
7,191
Death reported
1,226
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- toxicity to various agents1,252
- drug ineffective1,156
- tremor1,090
- drug interaction1,015
- nausea849
- weight increased824
- depression721
- insomnia721
- fatigue698
- vomiting676
- confusional state649
- somnolence643
- anxiety620
- off label use603
- suicide attempt590
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 576 |
| 2005 | 495 |
| 2006 | 795 |
| 2007 | 1,046 |
| 2008 | 755 |
| 2009 | 866 |
| 2010 | 842 |
| 2011 | 1,140 |
| 2012 | 1,430 |
| 2013 | 509 |
| 2014 | 413 |
| 2015 | 632 |
| 2016 | 720 |
| 2017 | 604 |
| 2018 | 730 |
| 2019 | 690 |
| 2020 | 693 |
| 2021 | 772 |
| 2022 | 749 |
| 2023 | 727 |
| 2024 | 661 |
| 2025 | 600 |
| 2026 | 533 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,037,181 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| suicide attemptSignal | 590 | 12.2 | 11.2 | 5,992 |
| toxicity to various agentsSignal | 1,252 | 9.3 | 8.8 | 9,220 |
| tremorSignal | 1,090 | 8.2 | 7.7 | 6,875 |
| drug interactionSignal | 1,015 | 8.0 | 7.5 | 6,188 |
| confusional stateSignal | 649 | 5.0 | 4.6 | 2,075 |
| weight increasedSignal | 824 | 4.6 | 4.3 | 2,312 |
| somnolenceSignal | 643 | 4.0 | 3.7 | 1,432 |
| depressionSignal | 721 | 3.9 | 3.7 | 1,588 |
| insomniaSignal | 721 | 3.4 | 3.1 | 1,205 |
| anxietySignal | 620 | 2.7 | 2.5 | 671 |
| vomiting | 676 | 1.8 | 1.7 | 236 |
| nausea | 849 | 1.3 | 1.2 | 72 |
| fatigue | 698 | 1.1 | 1.0 | 8 |
| drug ineffective | 1,156 | 1.1 | 1.0 | 8 |
| off label use | 603 | 0.9 | 0.8 | 16 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.